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Contamination in trials: is cluster randomisation the
answer?
David J Torgerson
Most randomised trials allocate individual participants
to different treatments. However, cluster randomised
trials in which groups of subjects are allocated to
different treatments are becoming increasingly popu›
lar.1 Cluster randomisation is often advocated to mini›
mise treatment “contamination” between intervention
and control participants. For example, in a trial of
dietary change, people in the control group might
learn about the experimental diet and adopt it
themselves.
Contamination of control participants has two
related effects. It reduces the point estimate of an inter›
vention’s effectiveness and this apparent reduction may
lead to a type II error—that is, rejection of an effective
intervention as ineffective because the observed effect
size was neither statistically nor clinically significant.
Although the threat of contamination is an issue in
some controlled trials, it may be not be of much practi›
cal importance in many. Trialists should use individual
randomisation if possible because of the drawbacks of
cluster allocation. Cluster trials are associated with
problems of recruitment bias and the need for larger
samples than would be required in similar, individually
randomised trials. In recruitment bias, different sorts of
participants are selected into the various arms of the
trial, thereby defeating the objective of randomisation,
while a larger sample size may increase the cost of a
trial, its length, or its complexity. This paper describes
the difficulties of cluster trials and argues that the
problem of contamination can often be dealt with by
individual randomisation.
Sample size
Members of clusters cannot be treated as independent,
and the effect of this on outcomes leads to a need to
increase the sample size.1 2 This problem can also be
described as follows: for any given sample size, the cor›
relation between cluster members will reduce the over›
all power of the study. The difficulty is well known and
much has been published recently on sample size and
analytical issues.1–4
Selection bias in cluster trials
The randomised trial is the ideal study design in evalu›
ative research because of its ability to deal with known
and unknown confounding factors. If randomisation is
successful, these factors should be balanced across the
treatment groups. Balance in cluster trials can be
achieved through randomisation across the trial arms
at the cluster level if there are sufficient clusters. How›
ever, simple randomisation of clusters, even with
relatively large numbers, can still result in an
imbalance. For instance, in a randomised trial of breast
screening there was an imbalance in socioeconomic
groups between the two study arms even though 87
clusters (general practices) and 50 000 women were
included.5 This imbalance would have been extremely
unlikely had the trial used individual randomisation.
Cluster trials generally use the postrandomised
consent method of trial design, which is similar in con›
cept to Zelen’s method in individually randomised
designs.6 Participants are not asked for their consent to
randomisation; they are usually asked for consent to
treatment (although this is not always done in cluster
trials) and are asked whether they consent to inclusion
in the study analysis. When cluster trials are analysed at
the individual level using this method, balance between
the randomised groups can only be guaranteed if one
of two conditions are fulfilled: all members of the clus›
ter must be included in the trial, or a random sample of
participants must be included in the trial’s analysis. The
latter approach may be used to increase the statistical
power of the study for a given sample size by increasing
the number of clusters rather than the total number of
patients.4 For instance, Kerse et al took a random sam›
ple of patients from each cluster rather than all
randomised individuals.7 Neither of these conditions
has been met in recently published cluster trials. Often
participants are asked after randomisation whether
they will participate in the trial in terms of providing
data for follow up. If a significant proportion refuses,
there is a possibility of selection bias.
Observable characteristics
An example of selection bias was seen in a recent trial
of counselling to reduce the risk of cardiovascular dis›
ease.8 Participants were allowed the choice of accepting
the intervention and providing data on outcomes. Par›
ticipation in the control arm was more desirable than
participation in the intervention, as a result of which
nearly twice as many subjects were recruited as
controls. Moreover, the participants in the intervention
group had some observable characteristics, such as a
lower prevalence of smoking, which put them at a
lower risk of coronary heart disease than the control
group. Thus, the modest effect associated with the
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intervention could have been due to the recruitment of
different types of participant rather than the interven›
tion. Similarly, in a cluster trial of diabetes care the
intervention clusters identified about 25% more
eligible patients than the control clusters, although the
total size of the list of patients was slightly greater in the
control clusters.9
Unobserved characteristics
Even when recruitment between the intervention and
control clusters is similar and the observed baseline
characteristics between allocation groups seem bal›
anced, if not all the members of the cluster or a
random sample of them are included in the analysis,
the trial may still be unbalanced because of unobserved
characteristics. For example, in a trial of a behavioural
intervention to prevent violence in schools, the
number of pupils in the two groups was similar, but
only 66% of children—those whose parents had
returned consent forms—were included in the study.10
However, the intervention was still delivered to
children whose parents had not returned consent
forms. Although the trial recorded a creditable 82%
follow up, this represented only 54% of the entire ran›
domised sample. In contrast, a trial of accident preven›
tion in children included all relevant members of the
cluster in the analysis (children aged 3›12 months) and
managed to collect and analyse outcome data on more
than 92%, thus reassuring us that little, if any, selection
bias had taken place.11
Reduced power: Zelen’s method
When Zelen’s method is used in an individually
randomised trial there is usually a loss of statistical
power because there is incomplete penetration of the
intervention. Thus, uptake of a new treatment that is
less than 100% will lead to a dilution of the effect of
treatment and will reduce the measurable effect size.12
Because cluster trials also use Zelen’s method, this dilu›
tion of effect applies to them too. For example, in a
cluster trial of injury prevention in young children the
intervention was not delivered to about 25% of parents
in the experimental arm.11 This problem is not gener›
ally recognised in estimating the sample size for cluster
trials, and if it is taken into account it will lead to a gen›
eral increase in sample sizes. Thus, some cluster trials
not only need to account for the clustering effects on
statistical power, they also need to boost sample sizes
because of the dilution effect.
Dealing with contamination
Before considering cluster randomisation as a way of
addressing contamination we need to be certain that
contamination is a real rather than a theoretical possi›
bility. Are patients who are receiving counselling really
going to pass on the intervention in such a way as to
alter behaviour in the control arm of a trial? This thesis
could be tested empirically by undertaking a pilot trial
using individual randomisation with contamination of
the control group as the outcome. However, even if
contamination were a problem and a sizeable
proportion of the control group was affected,
individual randomisation might still be best.
As an example, consider a trial of counselling to
promote healthy behaviour in adults at high risk of
cardiovascular disease.8 To detect a 9% reduction in
smoking prevalence from 50% to 41% with 90% power
at a significance value of 5%, a total of 1282
participants would have been needed. However,
because the trialists elected to use a cluster design a
sample of 2000 was required. The trialists could have
chosen individual randomisation with a sample size of
2000 and utilised the extra power of this increased
sample to cope with any contamination. Thus, a sample
of 2000 would have been able to detect a 7% difference
in smoking prevalence with 90% power and 5% signifi›
cance, allowing for up to a 20% contamination of the
control group. Furthermore, this estimate of the allow›
able contamination assumes that the effectiveness of
the intervention through contamination is as powerful
as if it had been delivered by healthcare professionals.
However, if we assume that it was only half as effective,
contamination could be much greater. Indeed, if
contamination in this particular trial had been
theoretical, the non›significant effect size noted in the
trial would have been significant if individual randomi›
sation had been used.
Effects of contamination on sample size
The probable scale of contamination will clearly differ
with the intervention, and I am not aware of any pub›
lished estimates in trials that might have used a cluster
design to avoid contamination. However, a review of
Zelen’s method in cancer trials that did not use cluster
randomisation showed that the mean proportion of
patients who crossed from one treatment to another,
which is analogous to contamination, was 18% (range
10%›36%).12 The tables show the impact that different
intracluster correlation coefficients and contamination
rates have on estimates of sample size or contamina›
tion. Around 30% contamination can be sustained
before the sample size has to be doubled to take into
account the reduced effect size from such contamina›
tion. However, use of cluster randomisation rapidly
leads to a doubling of the sample size. Even if the intra›
cluster coefficient of correlation is very low, the clusters
are small, and there are relatively high levels of
contamination, individual randomisation can still
result in a smaller sample size.
Reduced effect size
Although some contamination can be dealt with by
increasing the sample size, a trial might still show a sta›
tistically significant effect but one that is too small to be
of clinical relevance. Trials are rarely powered on the
basis of a minimum clinical significance. Rather, they
are powered on the likely effect that other trials have
detected or on the basis of observational work or on
logistical factors. Thus, the reduced effect size caused
Table 1 Numbers of participants required in an individually randomised trial to detect a
difference between two groups where the true effect size is 25%
Contamination (%)
0 5 10 15 20 25 30
Sample size 116 126 144 164 182 200 236
Contamination effect 1 1.09 1.24 1.41 1.58 1.72 2.03
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by contamination could be used to calculate sample
sizes.
Discussion
Often a cluster design is the correct design for a trial.
For instance, a randomised trial of training teachers to
promote smoking cessation demanded a cluster design
as it would not have been practical to randomise
children to different teachers.13 In these instances one
must be aware of the potential problems of selection
bias creeping into the study. However, there is
uncertainty with many trials. Thus, recent cluster trials
which probably could have used an individually
randomised design include a vitamin A supplementa›
tion study,14 an accident prevention trial,11 and a
lifestyle behaviour changes study.8 Because of the
problems outlined in this paper, trialists ought to con›
sider very carefully the cluster approach to trial design.
Substantial contamination can be tolerated within the
usual individual randomised trial before a cluster
design is better in terms of total sample size.
I thank Hazel Inskip, the BMJ ’s referee, for helpful comments on
the original manuscript.
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Table 2 Numbers of participants required in a cluster trial to detect a difference
between two groups where the true effect size is 25%
Cluster size
Intracluster correlation coefficient 1 10 20 30 40 50 100
0.01:
Sample size 116 126 139 150 161 173 231
Design effect 1 1.09 1.20 1.29 1.39 1.49 1.99
0.02:
Sample size 116 137 160 184 207 230 346
Design effect 1 1.18 1.38 1.59 1.78 1.98 2.98
0.03
Sample size 116 148 182 218 252 287 461
Design effect 1 1.27 1.57 1.88 2.17 2.47 3.97
A memorable patient
A life saving procedure
A 34 year old temple priest from the Maharashtra district of
central India was on his way home from a pilgrimage to a temple
in northern India. He had been suffering from diarrhoea and
vomiting for the past 12 hours. He thought he would cope with it
until he arrived home and saw his doctor. But he was wrong. He
was fast losing body water and getting colder. I know because I
was travelling in the same train, in the same compartment. He
was weak and could barely open his eyes. His pulse was weak,
thready, and rapid, his extremities were cold and he was
perspiring. I told his wife that he needed at least two lines in his
arms and lots of fluids.
I requested the ticket checker to bring an emergency kit, but
when I opened it I found it did not have intravenous fluids. All I
could do was to give him an injection to keep up his blood
pressure. The next stop was three and a half hours away, and that
was too long for him. I discussed this again with his wife, and by
now everybody in the compartment was involved. A unanimous
decision was made to pull the chain and stop the train at some
station on the way.
But then came the next problem. All the chains turned out to
be jammed. It was a real surprise and nobody knew what to do
next. There was no way of communication between the ticket
checker and the driver.
I then suggested that when the train slowed down at some
station on the way we should drop a note carrying a message for
the station master to alert the master at the next station to halt
our train there. We wrapped the note round a five rupee coin and
threw it near enough for the signalman to notice. It worked. The
train was stopped at the next station and the priest was lifted away
to hospital, while his wife kept on thanking me.
I felt frustrated at not being of much help to him, and angry at
the rail authorities for their negligence. Also I thought I would
never be able to find out how the priest was.
Surprisingly, his wife had checked on the list of passengers and
found my address, because when I reached home I found a letter
of thanks from the priest. He had made an uneventful recovery
after two days in hospital. After that he kept writing to me
because he thought I had helped save his life—not because of the
injection but because I had come up with the idea of stopping the
train. Recently he has invited me to his elder daughter’s wedding.
Kalpesh Shah clinical observer, Ipswich
We welcome articles of up to 600 words on topics such as
A memorable patient, A paper that changed my practice,My most
unfortunate mistake, or any other piece conveying instruction,
pathos, or humour. If possible the article should be supplied on a
disk. Permission is needed from the patient or a relative if an
identifiable patient is referred to. We also welcome contributions
for “Endpieces,” consisting of quotations of up to 80 words (but
most are considerably shorter) from any source, ancient or
modern, which have appealed to the reader.
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